FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2283207608> ?p ?o ?g. }

• W2283207608 endingPage "1040" @default.
• W2283207608 startingPage "1040" @default.
• W2283207608 abstract "1040 Background: Although sentinel lymph node biopsy (SLNB) is a common procedure in treatment of early stage breast cancer, SLN examination protocols have not been standardized. OSNA assay is a semi-automated lymph node examination method using molecular biological technique and has been valued as a tool for the intraoperative SLN examination with potential for standardization. Also, OSNA assay is quite unique in providing semi-quantitative result (++/+) reflecting volume of metastatic foci by measuring the amount of CK19mRNA in a lymph node. This study evaluated clinical utility of OSNA assay in the clinical setting at 10 institutes in Japan. Methods: 415 clinically node negative breast cancer patients scheduled for SLNB were enrolled. Each surgically-obtained SLN was applied to both postoperative pathological examination and OSNA assay; a central slice of each SLN with 1 mm thickness was applied to pathological examination for one section H&E staining, and the residual portion was applied to OSNA assay. For patients who received axillary dissection (ALND), non-SLN status was examined by routine method at each site. Results: OSNA showed significantly high number of positive patients over pathological examination (94 patients by OSNA assay vs. 67 patients by pathological examination). Among 35 patients who were judged as SLN positive only by OSNA assay, 32 patients received ALND and 6 (18.8%) of these patients had metastases in non-SLN. Among those who received ALND, 50 patients showed OSNA ++ and 34 patients OSNA +, with metastases in non-SLN in 22 patients and 6 patients respectively. Positive predictive value of OSNA ++ for non-SLN metastasis (22/50 = 44.0%) was significantly higher than that of OSNA + (6/34 = 17.6%) (p=0.01). Conclusions: These results suggest that OSNA assay can be more sensitive for detection of SLN metastases than pathological examination using one section H&E staining and semi-quantitative result of OSNA (++/+) defined by the amount of CK19mRNA can be a strong predictive factor of additional non-SLN involvement." @default.
• W2283207608 created "2016-06-24" @default.
• W2283207608 creator A5000846644 @default.
• W2283207608 creator A5003489811 @default.
• W2283207608 creator A5013313218 @default.
• W2283207608 creator A5014906183 @default.
• W2283207608 creator A5022263069 @default.
• W2283207608 creator A5022518251 @default.
• W2283207608 creator A5036050363 @default.
• W2283207608 creator A5044104698 @default.
• W2283207608 creator A5045341160 @default.
• W2283207608 creator A5048832660 @default.
• W2283207608 creator A5052449891 @default.
• W2283207608 creator A5062739693 @default.
• W2283207608 creator A5063623048 @default.
• W2283207608 creator A5064723247 @default.
• W2283207608 creator A5064748731 @default.
• W2283207608 creator A5065159945 @default.
• W2283207608 creator A5067390502 @default.
• W2283207608 creator A5075853905 @default.
• W2283207608 creator A5076758044 @default.
• W2283207608 creator A5088184018 @default.
• W2283207608 date "2011-05-20" @default.
• W2283207608 modified "2023-09-26" @default.
• W2283207608 title "Multi-institutional evaluation of sentinel lymph node (SLN) examination by one-step nucleic acid amplification (OSNA) assay in breast cancer: Performance of metastases detection and prediction of additional non-sentinel lymph node (non-SLN) involvement." @default.
• W2283207608 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.1040" @default.
• W2283207608 hasPublicationYear "2011" @default.
• W2283207608 type Work @default.
• W2283207608 sameAs 2283207608 @default.
• W2283207608 citedByCount "2" @default.
• W2283207608 countsByYear W22832076082015 @default.
• W2283207608 countsByYear W22832076082017 @default.
• W2283207608 crossrefType "journal-article" @default.
• W2283207608 hasAuthorship W2283207608A5000846644 @default.
• W2283207608 hasAuthorship W2283207608A5003489811 @default.
• W2283207608 hasAuthorship W2283207608A5013313218 @default.
• W2283207608 hasAuthorship W2283207608A5014906183 @default.
• W2283207608 hasAuthorship W2283207608A5022263069 @default.
• W2283207608 hasAuthorship W2283207608A5022518251 @default.
• W2283207608 hasAuthorship W2283207608A5036050363 @default.
• W2283207608 hasAuthorship W2283207608A5044104698 @default.
• W2283207608 hasAuthorship W2283207608A5045341160 @default.
• W2283207608 hasAuthorship W2283207608A5048832660 @default.
• W2283207608 hasAuthorship W2283207608A5052449891 @default.
• W2283207608 hasAuthorship W2283207608A5062739693 @default.
• W2283207608 hasAuthorship W2283207608A5063623048 @default.
• W2283207608 hasAuthorship W2283207608A5064723247 @default.
• W2283207608 hasAuthorship W2283207608A5064748731 @default.
• W2283207608 hasAuthorship W2283207608A5065159945 @default.
• W2283207608 hasAuthorship W2283207608A5067390502 @default.
• W2283207608 hasAuthorship W2283207608A5075853905 @default.
• W2283207608 hasAuthorship W2283207608A5076758044 @default.
• W2283207608 hasAuthorship W2283207608A5088184018 @default.
• W2283207608 hasConcept C121608353 @default.
• W2283207608 hasConcept C126322002 @default.
• W2283207608 hasConcept C126838900 @default.
• W2283207608 hasConcept C142724271 @default.
• W2283207608 hasConcept C146357865 @default.
• W2283207608 hasConcept C151730666 @default.
• W2283207608 hasConcept C207886595 @default.
• W2283207608 hasConcept C2775934546 @default.
• W2283207608 hasConcept C2779013556 @default.
• W2283207608 hasConcept C2779720271 @default.
• W2283207608 hasConcept C2780212769 @default.
• W2283207608 hasConcept C2780849966 @default.
• W2283207608 hasConcept C2908949552 @default.
• W2283207608 hasConcept C530470458 @default.
• W2283207608 hasConcept C71924100 @default.
• W2283207608 hasConcept C86803240 @default.
• W2283207608 hasConceptScore W2283207608C121608353 @default.
• W2283207608 hasConceptScore W2283207608C126322002 @default.
• W2283207608 hasConceptScore W2283207608C126838900 @default.
• W2283207608 hasConceptScore W2283207608C142724271 @default.
• W2283207608 hasConceptScore W2283207608C146357865 @default.
• W2283207608 hasConceptScore W2283207608C151730666 @default.
• W2283207608 hasConceptScore W2283207608C207886595 @default.
• W2283207608 hasConceptScore W2283207608C2775934546 @default.
• W2283207608 hasConceptScore W2283207608C2779013556 @default.
• W2283207608 hasConceptScore W2283207608C2779720271 @default.
• W2283207608 hasConceptScore W2283207608C2780212769 @default.
• W2283207608 hasConceptScore W2283207608C2780849966 @default.
• W2283207608 hasConceptScore W2283207608C2908949552 @default.
• W2283207608 hasConceptScore W2283207608C530470458 @default.
• W2283207608 hasConceptScore W2283207608C71924100 @default.
• W2283207608 hasConceptScore W2283207608C86803240 @default.
• W2283207608 hasIssue "15_suppl" @default.
• W2283207608 hasLocation W22832076081 @default.
• W2283207608 hasOpenAccess W2283207608 @default.
• W2283207608 hasPrimaryLocation W22832076081 @default.
• W2283207608 hasRelatedWork W1540164774 @default.
• W2283207608 hasRelatedWork W1966886751 @default.
• W2283207608 hasRelatedWork W1969892743 @default.
• W2283207608 hasRelatedWork W1995700936 @default.
• W2283207608 hasRelatedWork W2093959080 @default.
• W2283207608 hasRelatedWork W2130546155 @default.
• W2283207608 hasRelatedWork W2357874050 @default.
• W2283207608 hasRelatedWork W2401888051 @default.
• W2283207608 hasRelatedWork W2416765624 @default.

• next